The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Updates from the FLAIR trial: IR vs. FCR for CLL
In this video, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, University of Leeds, Leeds, UK, presents a summary of the first results from the ongoing Phase III FLAIR trial (ISRCTN01844152), which aims to compare the use of ibrutinib and rituximab (IR) versus fludarabine, cyclophosphamide and rituximab (FCR) in the treatment of patients with chronic lymphocytic leukemia (CLL). Dr Hillmen explains the significant advantages observed when using IR, including improved progression-free survival (PFS), especially in the IGHV unmutated and (del)11q subset of patients. To conclude, Dr Hillmen discusses some side effects that were seen in both treatment regimens, such as cardiac events and secondary myelodysplastic syndromes/ acute myeloid leukemia (MDS/AML). This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
